1. Home
  2. CALC vs GRCE Comparison

CALC vs GRCE Comparison

Compare CALC & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • GRCE
  • Stock Information
  • Founded
  • CALC 2011
  • GRCE 2002
  • Country
  • CALC United States
  • GRCE United States
  • Employees
  • CALC N/A
  • GRCE 4
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • GRCE
  • Sector
  • CALC Health Care
  • GRCE
  • Exchange
  • CALC Nasdaq
  • GRCE NYSE
  • Market Cap
  • CALC 36.0M
  • GRCE 35.6M
  • IPO Year
  • CALC N/A
  • GRCE N/A
  • Fundamental
  • Price
  • CALC $2.75
  • GRCE $3.51
  • Analyst Decision
  • CALC Strong Buy
  • GRCE
  • Analyst Count
  • CALC 5
  • GRCE 0
  • Target Price
  • CALC $18.20
  • GRCE N/A
  • AVG Volume (30 Days)
  • CALC 31.0K
  • GRCE 111.8K
  • Earning Date
  • CALC 03-27-2025
  • GRCE 02-21-2025
  • Dividend Yield
  • CALC N/A
  • GRCE N/A
  • EPS Growth
  • CALC N/A
  • GRCE N/A
  • EPS
  • CALC N/A
  • GRCE N/A
  • Revenue
  • CALC N/A
  • GRCE N/A
  • Revenue This Year
  • CALC N/A
  • GRCE N/A
  • Revenue Next Year
  • CALC N/A
  • GRCE N/A
  • P/E Ratio
  • CALC N/A
  • GRCE N/A
  • Revenue Growth
  • CALC N/A
  • GRCE N/A
  • 52 Week Low
  • CALC $2.05
  • GRCE $2.13
  • 52 Week High
  • CALC $6.27
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • CALC 46.50
  • GRCE N/A
  • Support Level
  • CALC $2.59
  • GRCE N/A
  • Resistance Level
  • CALC $2.73
  • GRCE N/A
  • Average True Range (ATR)
  • CALC 0.25
  • GRCE 0.00
  • MACD
  • CALC 0.01
  • GRCE 0.00
  • Stochastic Oscillator
  • CALC 50.59
  • GRCE 0.00

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Share on Social Networks: